Indian AI Platform for Cancer Care Debuts in BRICS Health Journal
iOncology.ai, an AI-driven cancer care platform, is spotlighted in the BRICS Health Journal, highlighting India's innovation in healthcare technology.
An Indian artificial intelligence platform, iOncology.ai, designed to enhance cancer care, has garnered international attention through its feature in the BRICS Health Journal. The platform, a collaborative effort by the All India Institute of Medical Sciences (AIIMS) in New Delhi and the Centre for Development of Advanced Computing (C-DAC) in Pune, is supported by the Ministry of Electronics and Information Technology.
AI-Driven Innovation in Cancer Care
The platform aims to integrate cancer-related clinical data to assist in early detection, risk stratification, treatment planning, and longitudinal patient-data management. This initiative is part of a broader effort to address cancer care disparities across the Global South, particularly in resource-constrained settings. The feature, "Transforming Cancer Care in Emerging Economies: India’s AI Innovation," authored by Dr. Ashok Sharma and colleagues from AIIMS and C-DAC, explores the potential of AI to improve cancer screening, diagnosis, and access to specialist care.
Global Implications and Next Steps
The BRICS countries, representing over 40% of the global population, face significant cancer challenges, with approximately 9 million new cases and 4.66 million deaths annually. The review emphasizes the importance of evidence-based, interoperable solutions tailored to the needs of emerging economies. iOncology.ai is positioned within India's expanding digital-health infrastructure, which includes initiatives like population screening and the Ayushman Bharat Digital Mission.
Future Validation and Implementation
Currently, iOncology.ai is in the pilot stage of clinical validation and implementation evaluation. While it uses curated Indian clinical, radiological, and histopathological datasets, plans are underway to include genetic data and integrate with electronic health-record systems. However, the platform is not yet clinically validated, with ongoing research required to establish its diagnostic accuracy and clinical utility. Prospective multicentre validation is necessary before it can be widely adopted in clinical settings.
Dr. Ashok Sharma highlighted the opportunity for India to showcase how locally developed technologies like iOncology.ai can contribute to more equitable cancer care. Through BRICS collaboration, the focus remains on strengthening cancer prevention, diagnosis, and treatment through innovative solutions.